Nothing Special   »   [go: up one dir, main page]

ATE261303T1 - Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung - Google Patents

Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung

Info

Publication number
ATE261303T1
ATE261303T1 AT96931210T AT96931210T ATE261303T1 AT E261303 T1 ATE261303 T1 AT E261303T1 AT 96931210 T AT96931210 T AT 96931210T AT 96931210 T AT96931210 T AT 96931210T AT E261303 T1 ATE261303 T1 AT E261303T1
Authority
AT
Austria
Prior art keywords
enteric coating
layer
image
composition
production
Prior art date
Application number
AT96931210T
Other languages
English (en)
Inventor
Pawan Seth
Original Assignee
Pharma Pass Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9514492A external-priority patent/FR2742050A1/fr
Priority claimed from FR9602265A external-priority patent/FR2745181A1/fr
Priority claimed from FR9605082A external-priority patent/FR2747573A1/fr
Application filed by Pharma Pass Ii Llc filed Critical Pharma Pass Ii Llc
Application granted granted Critical
Publication of ATE261303T1 publication Critical patent/ATE261303T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96931210T 1995-09-21 1996-09-23 Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung ATE261303T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9511094 1995-09-21
FR9514492A FR2742050A1 (fr) 1995-12-07 1995-12-07 Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation
FR9602265A FR2745181A1 (fr) 1996-02-23 1996-02-23 Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation
FR9605082A FR2747573A1 (fr) 1996-04-23 1996-04-23 Nouvelle composition contenant un benzimidazole acido-labile et son procede de preparation
PCT/IB1996/001054 WO1997012580A2 (en) 1995-09-21 1996-09-23 Novel composition containing an acid-labile benzimidazole and process for its preparation

Publications (1)

Publication Number Publication Date
ATE261303T1 true ATE261303T1 (de) 2004-03-15

Family

ID=27446956

Family Applications (4)

Application Number Title Priority Date Filing Date
AT00127495T ATE262332T1 (de) 1995-09-21 1996-09-23 Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
AT03001111T ATE286394T1 (de) 1995-09-21 1996-09-23 Ein säurelabile omeprazol enthaltende arzneizusammensetzung und verfahren zu deren herstellung
AT96931210T ATE261303T1 (de) 1995-09-21 1996-09-23 Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
AT96931211T ATE241357T1 (de) 1995-09-21 1996-09-23 Säurelabile omeprazol enthaltende pharmazeutische zusammensetzung und verfahren zu dessen herstellung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT00127495T ATE262332T1 (de) 1995-09-21 1996-09-23 Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
AT03001111T ATE286394T1 (de) 1995-09-21 1996-09-23 Ein säurelabile omeprazol enthaltende arzneizusammensetzung und verfahren zu deren herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96931211T ATE241357T1 (de) 1995-09-21 1996-09-23 Säurelabile omeprazol enthaltende pharmazeutische zusammensetzung und verfahren zu dessen herstellung

Country Status (19)

Country Link
US (3) US6159499A (de)
EP (4) EP0859612B1 (de)
JP (2) JP3463266B2 (de)
KR (1) KR100350138B1 (de)
CN (1) CN1093855C (de)
AT (4) ATE262332T1 (de)
AU (2) AU713242B2 (de)
CA (1) CA2231223C (de)
CZ (1) CZ293595B6 (de)
DE (4) DE69631834T2 (de)
DK (4) DK1308159T3 (de)
ES (4) ES2220989T3 (de)
HU (1) HU227566B1 (de)
NO (1) NO320489B1 (de)
NZ (1) NZ318501A (de)
PL (1) PL186605B1 (de)
PT (4) PT854718E (de)
SK (1) SK284291B6 (de)
WO (2) WO1997012580A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3542189B2 (ja) * 1995-03-08 2004-07-14 株式会社ルネサステクノロジ 半導体装置の製造方法及び半導体装置
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
ATE321538T1 (de) 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US7220762B1 (en) * 1999-10-20 2007-05-22 Eisai R&D Management Co., Ltd. Methods for stabilizing benzimidazole compounds
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
ATE508725T1 (de) * 2001-06-20 2011-05-15 Takeda Pharmaceutical Verfahren zur herstellung von tabletten
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
DE60239945D1 (de) 2001-09-28 2011-06-16 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
EP1474108A2 (de) 2002-01-09 2004-11-10 Enzrel, Inc. Liposom-arzneimittelabgabe von polyzyklischen, aromatischen, antioxidativen oder antiphlogistischen verbindungen
DE60327478D1 (de) * 2002-03-11 2009-06-10 Dow Global Technologies Inc Reversible thermofixierte elastische Fasern, Herstellungsverfahren und daraus hergestellte Artikel
CN100564659C (zh) * 2002-03-11 2009-12-02 陶氏环球技术公司 具有改进的化学耐久性和稳定性的弹力织物
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
CA2511540A1 (en) * 2002-12-23 2004-07-22 Celltech Americas, Inc. Acid labile drug compositions
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
KR20060065632A (ko) * 2003-07-17 2006-06-14 닥터 레디스 래보러토리즈, 인코포레이티드 팽창성 코팅을 갖는 약제학적 조성물
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CA2536902A1 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1667681A4 (de) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd Neues transmukosales abgabesystem
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
TW200626185A (en) * 2004-12-17 2006-08-01 Bpsi Holdings Inc Enteric film coating composition containing entericpolymer micronized with detackifier
RU2007123436A (ru) * 2004-12-20 2009-01-27 Др. Редди` Лабораторис Лтд. (IN) Фармацевтическая композиция, содержащая аморфные соединения бензимидазола, и способ ее приготовления
CN101111233A (zh) 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 稳定的口服苯并咪唑组合物及其制备方法
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
CN100393304C (zh) * 2005-02-28 2008-06-11 上海艾力斯医药科技有限公司 一种包含酸不稳定药物的微细颗粒及其制剂
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
ES2278511B1 (es) * 2005-07-28 2008-06-16 Laboratorios Almirall S.A. Comprimidos con perfil de disolucion mejorado.
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1813275A1 (de) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd In der Mundhöle zerfallende Lansoprazol-Tabletten
JP2009524592A (ja) * 2005-12-20 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP2535045A1 (de) * 2011-06-15 2012-12-19 Laboratorios Del. Dr. Esteve, S.A. Pharmazeutische Zusammensetzung von Lansoprazol
CN102846571A (zh) * 2012-09-29 2013-01-02 南京正科制药有限公司 一种埃索美拉唑镁微型片剂
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN113116894A (zh) * 2019-12-30 2021-07-16 北京康辰药业股份有限公司 一种抗肿瘤药物组合物以及提高化合物的溶解度的方法
GB202116644D0 (en) 2021-11-18 2022-01-05 Innovate Pharmaceuticals Ltd Liquid composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IN148930B (de) * 1977-09-19 1981-07-25 Hoffmann La Roche
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
HU195220B (en) * 1983-05-03 1988-04-28 Byk Gulden Lomberg Chem Fqb Process for production of new fluor-alkoxi-benzimidasole-derivatives and medical compositions containig them
DE3415971A1 (de) * 1983-05-03 1984-11-08 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Acylierte benzimidazole, verfahren zu ihrer herstellung, ihre anwendung und sie enthaltende arzneimittel
IL71665A (en) * 1983-05-03 1988-05-31 Byk Gulden Lomberg Chem Fab Fluoro-(2-pyridyl-methylthio)-dioxolo-(and dioxino-)benzimidazoles,processes for their preparation and pharmaceutical compositions containing the same
GR81595B (de) * 1983-06-18 1984-12-11 Wyeth John & Brother Ltd
CA1259070A (en) * 1983-07-01 1989-09-05 Upjohn Company (The) Substituted 2-¬monoannelated(3,4-,4,5-, and 5,6-)- pyridylalkylenesulfinyl|-benzimidazoles
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
IE57646B1 (en) * 1983-12-16 1993-02-10 Wyeth John & Brother Ltd Derivatives of imidazoquinolines and analogues thereof
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US5250527A (en) * 1985-10-24 1993-10-05 Smithkline & French Laboratories Limited Pyridyl containing benzimidazoles, compositions and use
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US4828848A (en) * 1987-01-29 1989-05-09 Owades Joseph L Method of making salt-free pickles
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DK0519144T3 (da) * 1991-06-21 1998-03-23 Ilsan Ilac Ve Hammaddeleri San Ny galenisk proces for omeprazol indeholdende pellets
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
TW224049B (de) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SI0723436T1 (en) 1994-07-08 2002-02-28 Astrazeneca Ab Multiple unit tableted dosage form i
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II

Also Published As

Publication number Publication date
DE69634160D1 (de) 2005-02-10
AU713242B2 (en) 1999-11-25
HUP9900467A2 (hu) 1999-09-28
EP1092434A1 (de) 2001-04-18
DE69631834D1 (de) 2004-04-15
DE69631834T2 (de) 2005-02-10
EP0854718A4 (de) 2000-04-26
JPH11504343A (ja) 1999-04-20
PT854718E (pt) 2004-08-31
DE69631981T2 (de) 2005-04-14
PL186605B1 (pl) 2004-01-30
DK0854718T3 (da) 2004-07-12
KR100350138B1 (ko) 2003-03-10
JP3198337B2 (ja) 2001-08-13
EP0854718A2 (de) 1998-07-29
EP0859612B1 (de) 2003-05-28
NO981284L (no) 1998-03-20
SK284291B6 (sk) 2005-01-03
US6248355B1 (en) 2001-06-19
EP0859612A4 (de) 1998-11-04
DK0859612T3 (da) 2003-09-22
DK1308159T3 (da) 2005-02-14
ATE262332T1 (de) 2004-04-15
NO320489B1 (no) 2005-12-12
NO981284D0 (no) 1998-03-20
WO1997012581A3 (en) 1997-06-12
AU6998796A (en) 1997-04-28
DE69631981D1 (de) 2004-04-29
CZ293595B6 (cs) 2004-06-16
EP1308159A1 (de) 2003-05-07
ES2218054T3 (es) 2004-11-16
WO1997012580A3 (en) 1997-06-12
ATE241357T1 (de) 2003-06-15
DE69634160T2 (de) 2005-12-22
ATE286394T1 (de) 2005-01-15
DE69628444D1 (de) 2003-07-03
PL325838A1 (en) 1998-08-03
ES2220989T3 (es) 2004-12-16
ES2201200T3 (es) 2004-03-16
NZ318501A (en) 1999-06-29
PT859612E (pt) 2003-10-31
EP0859612A2 (de) 1998-08-26
DE69628444T2 (de) 2004-05-06
US6159499A (en) 2000-12-12
CN1197456A (zh) 1998-10-28
CN1093855C (zh) 2002-11-06
CA2231223C (en) 2003-03-18
PT1308159E (pt) 2005-02-28
WO1997012581A2 (en) 1997-04-10
US6207198B1 (en) 2001-03-27
JP3463266B2 (ja) 2003-11-05
JPH10511117A (ja) 1998-10-27
HUP9900467A3 (en) 2001-09-28
SK31498A3 (en) 1998-12-02
WO1997012580A2 (en) 1997-04-10
EP0854718B1 (de) 2004-03-10
EP1092434B1 (de) 2004-03-24
PT1092434E (pt) 2004-08-31
CZ87998A3 (cs) 1998-08-12
ES2236628T3 (es) 2005-07-16
AU6998896A (en) 1997-04-28
CA2231223A1 (en) 1997-04-10
HU227566B1 (en) 2011-08-29
DK1092434T3 (da) 2004-07-26
EP1308159B1 (de) 2005-01-05

Similar Documents

Publication Publication Date Title
ATE261303T1 (de) Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
BR9915087A (pt) Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem
TNSN95075A1 (fr) Forme de dosage i d'unite multiple en comprime
ATE110379T1 (de) Therapeutisch aktive substituierte benzimidazole und verfahren zu ihrer herstellung.
IL162544A (en) Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound
ATA156590A (de) Mono-(2-ammonium-2-hydroxymethyl-1,3-propandiol (2r,cis)-1,2-epoxypropylphosphonat und verfahren zu dessen herstellung sowie pharmazeutische zusammensetzungen
ATA318687A (de) Neue benzimidazole, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0854718

Country of ref document: EP

EEIH Change in the person of patent owner